As of Thursday close, Evaxion Biotech A/S’s (NASDAQ:EVAX) stock was up $0.07, moving up 10.29 percent to $0.75. The average number of shares traded per day over the past five days has been 753,480 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0199 gain in that time frame. In the last twenty days, the average volume was 245,790, while in the previous 50 days, it was 130,560.
Since last month, EVAX stock retreated -23.47%. Shares of the company fell to $0.4701 on 09/19/23, the lowest level in the past month. A 52-week high of $3.52 was reached on 01/03/23 after having rallying from a 52-week low of $0.47. Since the beginning of this year, EVAX’s stock price has dropped by -57.75% or -$1.0250, and marked a new high 1 time. However, the stock has declined by -78.69% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, Evaxion Biotech A/S’s quick ratio stood at 2.80, while its current ratio was 2.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 4.00, and the total debt-to-equity ratio was 4.20. Based on annual data, EVAX earned $1.51 million in gross profit and brought in $25.26 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Evaxion Biotech A/S to report -$0.21 quarterly earnings, the actual figure was -$0.21 per share. During the quarter, the company generated -$5.68 million in EBITDA. The liabilities of Evaxion Biotech A/S were 14.22 million at the end of its most recent quarter ended June 29, and its total debt was $10.49 million.
Technical Picture
This quick technical analysis looks at Evaxion Biotech A/S’s (EVAX) price momentum. With a historical volatility rate of 266.21%, the RSI 9-day stood at 50.02% on 21 September.
With respect to its five-day moving average, the current Evaxion Biotech A/S price is up by +2.73% percent or $0.0199. At present, EVAX shares trade -23.47% below its 20-day simple moving average and -40.48% percent below its 100-day simple moving average. However, the stock is currently trading approximately -42.31% below its SMA50 and -66.22% below its SMA200.
Stochastic coefficient K was 38.26% and Stochastic coefficient D was 23.78%, while ATR was 0.1357. Given the Stochastic reading of 63.66% for the 14-day period, the RSI (14) reading has been calculated as 45.49%. As of today, the MACD Oscillator reading stands at -0.0643, while the 14-day reading stands at -0.0838.
Analyst Ratings
Evaxion Biotech A/S (EVAX) has been rated Overweight by analysts. According to 0 brokerage firms, EVAX is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Evaxion Biotech A/S stock as buy, with 2 recommending it as overweight.
With a median target price of $11.00, the current consensus forecast for the stock is $7.00 – $15.00. Based on these forecasts, analysts predict Evaxion Biotech A/S (EVAX) will achieve an average price target of $11.00.
